Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233426 | 0.78 | NPY5R (0.50) | — | |
| SCHEMBL3839355 | 0.77 | MCHR2 (0.61) | MCHR2HSD11B1FFAR1USP2TSHR | |
| SCHEMBL3837633 | 0.76 | MCHR2 (0.60) | MCHR2HSD11B1NPC1L1 | |
| SCHEMBL4984631 | 0.76 | MCHR2 (0.60) | MCHR2HSD11B1FFAR1SMN1; SMN2NPC1L1 | |
| SCHEMBL2585297 | 0.74 | MAPK1 (0.50) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL762618 | 0.73 | MCHR2 (0.58) | MCHR2HSD11B1FFAR1NPC1L1 | |
| SCHEMBL762613 | 0.73 | MCHR2 (0.57) | MCHR2HSD11B1NPC1L1LMNA | |
| SCHEMBL1577454 | 0.73 | ENPP2 (0.50) | MCHR2HSD11B1CCR2 | |
| SCHEMBL2592717 | 0.72 | L3MBTL1 (0.54) | — | |
| SCHEMBL11951958 | 0.70 | MGLL (0.40) | USP2TSHRSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | claimed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | claimed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | claimed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | claimed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | MCHR2 3111/4885HSD11B1 967/4885FFAR1 606/4885 |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | MCHR2 3111/4885HSD11B1 967/4885FFAR1 606/4885 |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | MCHR2 3111/4885HSD11B1 967/4885FFAR1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.